Showing results (1631-1640 of 3,507) with videos related to

Sort By:
Pageof 351
Eclinicalmedicine|May 30, 2024
Cost-effectiveness of diagnosis and treatment of early gestational diabetes mellitus: economic evaluation of the TOBOGM study, an international multicenter randomized controlled trialMohammad M Haque, W Kathy Tannous, William H Herman, et al.
Eclinicalmedicine|June 7, 2024
GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling studyHannah Moll, Eliane Frey, Philipp Gerber, et al.
Eclinicalmedicine|May 30, 2024
Dietary supplement for mood symptoms in early postpartum: a double-blind randomized placebo controlled trialJeffrey H Meyer, ZhaoHui Wang, Apitharani Santhirakumar, et al.
Eclinicalmedicine|June 3, 2024
Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort studyLuis Jara-Palomares, Behnood Bikdeli, David Jiménez, et al.
Eclinicalmedicine|June 3, 2024
Tattoos as a risk factor for malignant lymphoma: a population-based case-control studyChristel Nielsen, Mats Jerkeman, Anna Saxne Jöud
Eclinicalmedicine|July 25, 2024
Treatment with liraglutide or naltrexone-bupropion in patients with genetic obesity: a real-world studyMila S Welling, Cornelis J de Groot, Mostafa Mohseni, et al.
Eclinicalmedicine|July 15, 2024
Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBaseJunyi Shen, Rong Hu, Anqi Lin, et al.
Eclinicalmedicine|July 15, 2024
Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trialYuankai Shi, Keshu Zhou, Hui Zhou, et al.
Eclinicalmedicine|July 15, 2024
Hospital readmissions among adults living with and without HIV in the US: findings from the Nationwide Readmissions DatabaseXianming Zhu, Eshan U Patel, Stephen A Berry, et al.
Eclinicalmedicine|May 15, 2024
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation studyZhi-Cheng Jin, Jian-Jian Chen, Xiao-Li Zhu, et al.
Pageof 351